Author:
Baas P,Belderbos J S A,Senan S,Kwa H B,van Bochove A,van Tinteren H,Burgers J A,van Meerbeeck J P
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Bunn Jr PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C, Livinston R, Weiss GR, Hicks WJ, Gandara DR (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13 (7): 1632–1641
2. Bunn PA, Greco FA, Einhorn L (1986) Cyclophosphamide, doxorubicin, and etoposide as first-line therapy in limited small cell lung cancer. Semin Oncol 13 (3 Suppl 3): S45–S53
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (11): 1748–1756
4. Choy H, Devore III RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Centre Affiliate Network Study). Int J Radiat Oncol Biol Phys 47 (4): 931–937
5. EORTC. Phase II trials in the EORTC (1997) The Protocol Review Committee, the Data Centre, the Research and Treatment Division, and the New Drug Development Office. European Organization for Research and Treatment of Cancer. Eur J Cancer 33 (9): 1361–1363
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献